Angiotensin 1/2 (5-7): Atomic Profile of a Potent Vasoconstrictor Peptide

Executive Summary: Angiotensin 1/2 (5-7) is a tripeptide (H2N-Ile-His-Pro-OH) derived from the enzymatic processing of angiotensinogen in the renin-angiotensin system (RAS), acting as a potent vasoconstrictor and contributing to both cardiovascular regulation and viral pathogenesis (Oliveira et al., 2025). Its purity (98.36% by HPLC) and sequence are verified by APExBIO, with robust solubility in DMSO, ethanol, and water at concentrations ≥36.5 mg/mL, ≥50 mg/mL, and ≥50 mg/mL, respectively (APExBIO). The peptide enhances SARS-CoV-2 spike protein binding to AXL receptors, implicating it in COVID-19 research (Oliveira et al., 2025). It is supplied as a solid and should be stored at -20°C, with prompt use of solutions for optimal stability. This dossier clarifies its mechanistic, experimental, and translational boundaries for hypertension and viral research workflows.

Biological Rationale

Angiotensin 1/2 (5-7) is a biologically active oligopeptide fragment derived from the larger angiotensinogen precursor, which is synthesized in the liver. The peptide sequence H2N-Ile-His-Pro-OH represents amino acids 5–7 of the canonical angiotensin II (1–8). Angiotensin fragments are produced by sequential enzymatic cleavages in the renin-angiotensin system, a hormonal cascade central to cardiovascular and renal homeostasis (Oliveira et al., 2025). The RAS regulates blood pressure, fluid and electrolyte balance, and vascular tone through tightly controlled peptide-mediated signaling. Angiotensin 1/2 (5-7) acts as a potent vasoconstrictor, directly contributing to increased vascular resistance and blood pressure. Its physiological and pathophysiological relevance is underscored in both hypertension and COVID-19 research, where it modulates receptor-ligand interactions relevant to disease progression (Oliveira et al., 2025).

Mechanism of Action of Angiotensin 1/2 (5-7)

Angiotensin 1/2 (5-7) is generated from the enzymatic cleavage of angiotensin II, following upstream processing by renin and angiotensin-converting enzyme (ACE). This tripeptide retains high affinity for the angiotensin signaling pathway, primarily acting through vasoconstriction and dipsogenic (thirst-inducing) mechanisms. In vitro, angiotensin 1/2 (5-7) enhances the binding of the SARS-CoV-2 spike protein to AXL, a receptor implicated in viral entry, with greater potency than longer angiotensin peptides (Oliveira et al., 2025). The molecular formula is C17H27N5O4, and the molecular weight is 365.43 Da. The peptide's action is mediated by direct interaction with cell surface G protein-coupled receptors (GPCRs) and by modulating downstream effectors such as aldosterone and antidiuretic hormone (Oliveira et al., 2025). In the context of viral pathogenesis, angiotensin 1/2 (5-7) increases the affinity of spike protein–AXL binding, potentially promoting viral entry in cells with low ACE2 expression.

Evidence & Benchmarks

• Angiotensin 1/2 (5-7) is a validated product with ≥98.36% purity (HPLC) and confirmed sequence (mass spectrometry) (APExBIO).
• In binding assays, angiotensin 1/2 (5-7) and other N-terminally truncated angiotensin peptides enhance SARS-CoV-2 spike–AXL binding more potently than full-length angiotensin II (2.7-fold increase for angiotensin IV; similar trend for angiotensin (5-7)) (Oliveira et al., 2025).
• Solubility benchmarks: ≥36.5 mg/mL in DMSO, ≥50 mg/mL in ethanol, ≥50 mg/mL in water at 25°C, pH 7.4 (APExBIO).
• Storage stability: solid form stable at -20°C; solutions should be prepared fresh and used promptly to prevent degradation (APExBIO).
• Angiotensin 1/2 (5-7) is a key tool for dissecting RAS-mediated hypertension and for modeling SARS-CoV-2 receptor interactions in translational research (Interlink: Renilla-Luciferase).

Applications, Limits & Misconceptions

Angiotensin 1/2 (5-7) is used in studies exploring hypertension, cardiovascular signaling, and SARS-CoV-2 entry mechanisms. Its atomic precision and robust solubility make it optimal for in vitro and ex vivo assays (Interlink: Acetyl-Angiotensinogen). Compared with other site articles, this review uniquely integrates atomic-level evidence for both cardiovascular and viral pathogenesis contexts. Whereas prior discussions (see here) focused on clinical endpoints, this article clarifies molecular benchmarks, storage, and workflow nuances. The product, available from APExBIO as Angiotensin 1/2 (5-7) (SKU: A1049), is suitable for mechanistic, screening, and translational studies.

Common Pitfalls or Misconceptions

• Angiotensin 1/2 (5-7) is not a direct substitute for full-length angiotensin II (1–8) in all receptor signaling assays; receptor affinity and downstream effects can differ significantly (Oliveira et al., 2025).
• Improper storage (above -20°C) or delayed use of solutions leads to peptide degradation, reducing experimental reproducibility (APExBIO).
• Not all vasoconstrictive activity observed in vitro translates to in vivo efficacy; species and assay context matter (Oliveira et al., 2025).
• Angiotensin 1/2 (5-7) is not a therapeutic or diagnostic agent; it is strictly for research use only.
• Misapplication in COVID-19 studies without proper controls can confound interpretations of spike–receptor interactions.

Workflow Integration & Parameters

For optimal experimental results, reconstitute Angiotensin 1/2 (5-7) in DMSO, ethanol, or water at concentrations recommended by APExBIO (≥36.5 mg/mL in DMSO, ≥50 mg/mL in ethanol or water). Prepare aliquots and store at -20°C. Avoid repeated freeze-thaw cycles. Confirm peptide purity by HPLC before use. Use within 24 hours after solution preparation for maximal activity. For studies on blood pressure regulation or viral pathogenesis, titrate dosing for relevant cell or tissue models as guided by peer-reviewed protocols. For further workflow integration guidance, see this molecular insights article, which is extended here with more granular storage and solubility metrics.

Conclusion & Outlook

Angiotensin 1/2 (5-7) is a rigorously characterized, high-purity vasoconstrictor peptide, enabling precise dissection of the renin-angiotensin system and viral receptor interactions. Its atomic sequence, validated bioactivity, and robust solubility profile make it a benchmark tool for hypertension and COVID-19 pathogenesis research. As new evidence emerges, particularly on its role in modulating SARS-CoV-2 entry pathways, Angiotensin 1/2 (5-7) will remain central to both cardiovascular and infectious disease research. For verified sourcing and technical documentation, visit the APExBIO product portal.